from present users of IRIS
“Radiation oncologists at the University of
Pennsylvania compared portal images obtained with a conventional
metal-film cassette with the BioScan images. In these preliminary
studies, the physicians judged the BioScan portal images
to be better than the film image for verifying treatment
setup of prostate fields. In addition the BioScan Imager
provided at least equivalent if not better images for identification
of anatomical landmarks in the treatment of head and neck,
lung, pelvis and extremity lesions”.
Dr. Peter Bloch
University of Pennsylvania Medical Center, USA
“One has to imagine that
extremely precise means to prepare the treatment. Some
devices are available but when the time comes to apply
it, one is not quite sure of the position. With Bioscan’s
devices, it is like having an aiming device and the patient
can really be seen during the radiotherapy” (excerpt
of a Swiss television broadcast – May 2000).
Pr. R. Mirimanoff
Head of Radio-oncology Dept.
“Today no portal imager
(EPID) gives any satisfactory images. IRIS is the first
system to give quality images usable in routine work to
improve the balistic precision of the radiations.
It is the first system to give true dynamic images.
A precision increase in our daily work in the Hospital
Lyon-Sud should make it possible to cure 5% more patients
for ENT, chest, abdomen or pelvis cancers. This means,
in a service such as that of Lyon-Sud, excluding breast
cancer : 900 annual radiations – 40% recovery, 360
patients/year. 5% more means approx. 20 additional recoveries
Pr. JP Gérard
Head of Radiotherapy-Oncology Dept.
Centre Hospitalier Lyon-Sud, France
“The development of IRIS as an imaging system
for radiotherapy is extremely interesting. The quality
of the images you showed me is absolutely remarkable.
I am very interested to notice that there was no significant
difference between the images at 6MV and at 18MV. This
is an important factor in a department with variable energy
I wish to follow the development of this system and believe
it is a clear asset in radiotherapy”.
Pr. F. Eschwege
Head of Radiotherapy Dept.
Vice-Director of the Gustave-Roussy Institute, Paris,